NEW YORK (GenomeWeb) – Caprion Biosciences said today it has acquired biomarker and immune monitoring firm Primity Bio.
According to Caprion, the company plans to use Primity's assets to expand its existing immunology and molecular profiling business.
Financial and other terms of the deal were not disclosed
"The acquisition of Primity Bio provides us access to highly complementary and well-differentiated biomarker and immune monitoring services while considerably expanding our geographic reach to better support the global clinical needs of our clients," Martin LeBlanc, president and CEO of Montreal-based Caprion, said in a statement. "[T]his US expansion and the opportunity to work with the highly talented and innovative scientific team at Primity significantly enhances our ability to deliver on Caprion's service diversification and international expansion strategy."
"Primity's proprietary technologies for biomarker discovery, cell signaling analysis by flow cytometry, and combination of pre-clinical and clinical capabilities are true differentiators in the industry, and are highly complementary to Caprion's existing services and CAP/CLIA-certified laboratories," added Tom Wehrman, Primity's VP of R&D.
The acquisition of Freemont, California-based Primity follows Caprion's 2016 buy of European immune monitoring laboratory ImmuneHealth, which the company purchased to similarly build out its immunology business.